Eminyakeni yamuva nje, umphumela wama-immune checkpoint inhibitors ekwelapheni i-Hodgkin's lymphoma (HL) uyahlaba umxhwele, kepha lesi sifo kusamele sinqotshwe ngokuphelele. Usihlalo weMayo Clinic weLymphoma Group u-Ansell uthe sifunda kwi-biology ye-Hodgkin's lymphoma futhi sihlinzeka ngamathuba amaningi okwelashwa kwe-lymphoma ngokuzayo.
We talk about the effectiveness of PD-L1 blockade in HL, looking for deeper solutions, alternative drug combinations that are making progress, and potential pathways for future discovery.
U-Ansell ubalule icala lesiguli esine-HL. Wambiza ngobusuku obubodwa futhi wamemezela ukuthi usebenzisa imishanguzo ye-nivolumab (Opdivo) iyasebenza. Ngaphezu kwezinye izimpawu, isiguli sasinama-lymph node futhi sangabe sisaba nomakhwapheni. Ngokuqinisekile, kwavela ukuthi i-HL yakhe yayikhulula, kepha ngemuva kweminyaka emibili yokwelashwa, ayizange inyamalale ngokuphelele.
Njengesazi sokuvikela izifo, u-Ansell uthe udumele kakhulu. Ngokusobala, yize ukwelashwa kwakusebenza, amaseli omzimba awakhombisanga inkumbulo eyanele yokuzivikela. U-Ansell uthole enye into ephazamisayo ukuthi kubonakala sengathi iziguli kufanele ziphathwe ngale ndlela kukho konke ukuphila kwazo.
Ukubuyekeza ubufakazi be-nivolumab njengokwelashwa kwendawo yokuhlola, isigaba esisodwa sengalo yesibili i-CheckMate 205 sibuyele emuva / saphinde saphinde saphinde saphinde saphinde sibonise isilingo se-Hodgkin lymphoma (cHL), esaqinisekisa izinga lokuphendula jikelele (ORR) ngemuva kokulandelwa okuphakathi kwezinyanga eziyi-18) I-69%, isikhathi esiphakathi sokuphendula kwaba yizinyanga eziyi-16.6, kanti ukusinda okungenamkhawulo kokuqhubeka kwaba izinyanga eziyi-14.7.
The KEYNOTE-087 single-arm phase II study of pembrolizumab (Keytruda) for this disease, in which the ORR of the drug was 69.0%, and the complete remission rate (CR) was 22.4%, 31 patients responded ≥ 6 months.
Ucwaningo lweSigaba I JAVELIN luhlolisise i-avelumab (iBavencio) njengesibopho sokukhetha se-PD-L1 ku-r / r HL. U-Ansell uveze ukuthi i-ORR yazo zonke iziguli ezingama-31 ibiyi-41.9% kanti impendulo engaphelele ibiyi-25.8%. Isikhathi sokuphendula esiphakathi nezinyanga eziyi-1.5
Le ndlela izanywe ngokuhlanganisa amasosha omzimba okuhlola izivikeli mzimba nivolumab kanye ne-ipilimumab (Yervoy). INivolumab isebenza njenge-PD-L1 blocker, i-ipilimumab ihlose amasosha omzimba ukwehlisa-ukulawula indima ye-CTLA-4. Ku-CheckMate 039, lokhu kuholele ku-ORR ka-74% (n = 23) kanye ne-CR rate ka-19% (n = 6). Njengamanje, izivikeli mzimba zokuhlola izivikeli mzimba zithole imiphumela emihle ekwelapheni i-cHL, kepha kusese nokude okufanele kwenziwe, futhi asinakuba nethemba elingaboni.
